Stromal Genes Add Prognostic Information to Proliferation and Histoclinical Markers: A Basis for the Next Generation of Breast Cancer Gene Signatures

被引:15
|
作者
Mefford, Dwain [1 ]
Mefford, Joel [1 ]
机构
[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
来源
PLOS ONE | 2012年 / 7卷 / 06期
关键词
EXPRESSION SIGNATURES; IMMUNE-RESPONSE; MICROARRAY DATA; PREDICTS; CLASSIFICATION; CARCINOMA; SUBTYPES; THERAPY; SURVIVAL; INDEX;
D O I
10.1371/journal.pone.0037646
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: First-generation gene signatures that identify breast cancer patients at risk of recurrence are confined to estrogen-positive cases and are driven by genes involved in the cell cycle and proliferation. Previously we induced sets of stromal genes that are prognostic for both estrogen-positive and estrogen-negative samples. Creating risk-management tools that incorporate these stromal signatures, along with existing proliferation-based signatures and established clinicopathological measures such as lymph node status and tumor size, should better identify women at greatest risk for metastasis and death. Methodology/Principal Findings: To investigate the strength and independence of the stromal and proliferation factors in estrogen-positive and estrogen-negative patients we constructed multivariate Cox proportional hazards models along with tree-based partitions of cancer cases for four breast cancer cohorts. Two sets of stromal genes, one consisting of DCN and FBLN1, and the other containing LAMA2, add substantial prognostic value to the proliferation signal and to clinical measures. For estrogen receptor-positive patients, the stromal-decorin set adds prognostic value independent of proliferation for three of the four datasets. For estrogen receptor-negative patients, the stromal-laminin set significantly adds prognostic value in two datasets, and marginally in a third. The stromal sets are most prognostic for the unselected population studies and may depend on the age distribution of the cohorts. Conclusion: The addition of stromal genes would measurably improve the performance of proliferation-based first-generation gene signatures, especially for older women. Incorporating indicators of the state of stromal cell types would mark a conceptual shift from epithelial-centric risk assessment to assessment based on the multiple cell types in the cancer-altered tissue.
引用
收藏
页数:10
相关论文
共 27 条
  • [1] Prognostic stromal gene signatures in breast cancer
    Winslow, Sofia
    Leandersson, Karin
    Edsjo, Anders
    Larsson, Christer
    BREAST CANCER RESEARCH, 2015, 17
  • [2] Prognostic stromal gene signatures in breast cancer
    Sofia Winslow
    Karin Leandersson
    Anders Edsjö
    Christer Larsson
    Breast Cancer Research, 17
  • [3] Gene signatures provide independent prognostic information in elderly breast cancer patients
    Aguirre, Miguel Castresana
    Johansson, Annelie
    Lindstrom, Linda S.
    Tobin, Nick
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Prognostic Value of Gene Signatures and Proliferation in Lymph-Node-Negative Breast Cancer
    Jonsdottir, Kristin
    Assmus, Joerg
    Slewa, Aida
    Gudlaugsson, Einar
    Skaland, Ivar
    Baak, Jan P. A.
    Janssen, Emiel A. M.
    PLOS ONE, 2014, 9 (03):
  • [5] Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
    Lundberg, Arian
    Lindstrom, Linda S.
    Harrell, J. Chuck
    Falato, Claudette
    Carlson, Joseph W.
    Wright, Paul K.
    Foukakis, Theodoros
    Perou, Charles M.
    Czene, Kamila
    Bergh, Jonas
    Tobin, Nicholas P.
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 7512 - 7520
  • [6] Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
    Castresana-Aguirre, Miguel
    Johansson, Annelie
    Matikas, Alexios
    Foukakis, Theodoros
    Lindstroem, Linda S.
    Tobin, Nicholas P.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [7] Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
    Miguel Castresana-Aguirre
    Annelie Johansson
    Alexios Matikas
    Theodoros Foukakis
    Linda S. Lindström
    Nicholas P. Tobin
    Breast Cancer Research, 26
  • [8] Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer
    Guo, Xiangqian
    Zhu, Shirley X.
    Brunner, Alayne L.
    van de Rijn, Matt
    West, Robert B.
    BREAST CANCER RESEARCH, 2013, 15 (06):
  • [9] Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer
    Xiangqian Guo
    Shirley X Zhu
    Alayne L Brunner
    Matt van de Rijn
    Robert B West
    Breast Cancer Research, 15
  • [10] Time to move forward from "first-generation" prognostic gene signatures in early breast cancer
    Desmedt, Christine
    Michiels, Stefan
    Haibe-Kains, Benjamin
    Loi, Sherene
    Sotiriou, Christos
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (03) : 643 - 645